Area of research
Pulmonary and Respiratory Medicine · Radiology, Nuclear Medicine and Imaging
Research interest
Research focused on Cabozantinib and Enzalutamide, with related work in Prostate cancer, Bicalutamide, Nivolumab. Notable publications include 'Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study', 'Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma', and 'A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant...'.
CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study